Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically\* or cytologically\* confirmed colorectal cancer~  * Site of primary tumor must have been confirmed by endoscopy, radiography, or surgery~ * Metastatic disease NOTE: \*Patients with a history of surgically treated colorectal cancer who subsequently develop recurrent metastatic disease do not require histologic or cytologic confirmation of metastatic disease unless an interval of \> 5 years has elapsed between initial primary surgery and the development of metastases~* Measurable disease~  * At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan~* No known curative therapy exists~* No history or evidence of CNS disease by physical exam (e.g., primary brain tumor or brain or CNS metastases)~PATIENT CHARACTERISTICS:~Age~* 70 and over~Performance status~* ECOG 0-1~Life expectancy~* More than 3 months~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL~* No bleeding diathesis or coagulopathy~Hepatic~* Bilirubin normal~* AST and ALT ≤ 3 times upper limit of normal (ULN)~* INR \< 1.5 (unless on therapeutic anticoagulants)~* No unstable or uncompensated hepatic disease~Renal~* Creatinine \< 1.2 times ULN OR~* Creatinine clearance \> 60 mL/min~* No unstable or uncompensated renal disease~Cardiovascular~* No history of stroke~* No uncontrolled hypertension (i.e., blood pressure \> 150/100 mm Hg on medication)~* No myocardial infarction within the past year~* No New York Heart Association class II-IV congestive heart failure~* No unstable angina~* No serious cardiac dysrhythmia requiring medication~* No other clinically significant cardiovascular disease~* No other unstable or uncompensated cardiac disease~Pulmonary~* No unstable or uncompensated respiratory disease~Other~* Fertile patients must use effective contraception~* Able to receive oral medication~* No known hypersensitivity to fluorouracil or capecitabine~* No known dihydropyrimidine dehydrogenase deficiency~* No seizures not controlled by standard medical therapy~* No serious nonhealing wound, ulcer, or bone fracture~* No other malignancy within the past 5 years except completely excised nonmelanoma skin cancer (with no evidence of recurrent disease) or carcinoma in situ of the cervix~* No other severe or uncontrolled systemic disease~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior bevacizumab~Chemotherapy~* Prior adjuvant fluorouracil and leucovorin calcium allowed provided the last treatment was administered \> 6 months before the development of metastatic disease~* No prior chemotherapy for metastatic colon cancer~* No prior irinotecan or oxaliplatin~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics~* More than 28 days since prior and no concurrent major surgery~* More than 28 days since prior open biopsy~* More than 7 days since prior fine needle aspiration or core biopsy~Other~* More than 4 weeks since prior and no concurrent participation in another experimental drug study~* More than 30 days since prior non-approved or investigational drugs

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine twice daily on days 1-7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues